

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 3-9, 11, and 20-26 without prejudice to renewal.

1. (Previously presented) A method of reducing goblet cell hyperplasia in an airway of an individual, comprising:

administering to a patient suffering from airway hypersecretion of mucus due to airway goblet cell hyperplasia an epidermal growth factor receptor (EGF-R) antagonist that binds the EGF-R in an amount effective to reduce goblet cell hyperplasia, wherein the EGF-R antagonist is a tyrosine kinase inhibitor selective for EGF-R.

2.-11. (Canceled)

2 ~~12~~. (Original) The method of claim 1, wherein the antagonist is administered by injection.

3 ~~13~~. (Original) The method of claim ²~~12~~, wherein the antagonist is administered intravenously with a carrier in the form of normal saline solution.

4 ~~14~~. (Original) The method of claim 1, wherein the antagonist is administered by inhalation.

5 ~~15~~. (Original) The method of claim 1, wherein the antagonist is administered by liposome delivery.

6 ~~16~~. (Original) The method of claim ⁵~~15~~, wherein said liposome is sterically stabilized and administered intravenously.

17.-26. (Canceled)